CoChat

Bortezomib Induces Anti–Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation

Open access
Gulla, Annamaria, Morelli, Eugenio, Samur, Mehmet K., Botta, Cirino, Hideshima, Teru, Bianchi, Giada, Fulciniti, Mariateresa, Malvestiti, Stefano, Prabhala, Rao H., Talluri, Srikanth, Wen, Kenneth, Tai, Yu-Tzu, Richardson, Paul G., Chauhan, Dharminder, Sewastianik, Tomasz, Carrasco, Ruben D., Munshi, Nikhil C., Anderson, Kenneth C. · 2021 · Blood Cancer Discovery
Cited by 144

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

The proteasome inhibitor bortezomib induces apoptosis in multiple myeloma cells and has transformed patient outcome. Using in vitro as well as in vivo immunodeficient and immunocompetent murine multiple myeloma models, we here show that bortezomib also triggers immunogenic cell death (ICD), characterized by exposure of calreticulin on dying multiple myeloma cells, phagocytosis of tumor cells by dendritic cells, and induction of multiple myeloma–specific immunity. We identify a bortezomib-triggered specific ICD gene signature associated with better outcome in two independent cohorts of patients with multiple myeloma. Importantly, bortezomib stimulates multiple myeloma cell immunogenicity via activation of the cGAS/STING pathway and production of type I IFNs, and STING agonists significantly potentiate bortezomib-induced ICD. Our study therefore delineates mechanisms whereby bortezomib exerts immunotherapeutic activity and provides the framework for clinical trials of STING agonists with bortezomib to induce potent tumor-specific immunity and improve patient outcome in multiple myeloma. Significance: Our study demonstrates that cGAS/STING-dependent immunostimulatory activity mediates bortezomib anti-myeloma activity in experimental models and associates with clinical response to bortezomib in patients with multiple myeloma. These findings provide the rationale for clinical evaluation of STING agonists to further potentiate anti–multiple myeloma immune response. See related commentary by Zitvogel and Kroemer, p. 405. This article is highlighted in the In This Issue feature, p. 403

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2643-3230.bcd-21-0047

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 144

Metadata

Authors
Gulla, A., Morelli, E., Samur, M. K., Botta, C., Hideshima, T., Bianchi, G., Fulciniti, M., Malvestiti, S., Prabhala, R. H., Talluri, S., Wen, K., Tai, Y.-T., Richardson, P. G., Chauhan, D., Sewastianik, T., Carrasco, R. D., Munshi, N. C., & Anderson, K. C.
Venue
Blood Cancer Discovery
Published
2021-04-23
Volume
2
Issue
5
Pages
468-483
ISSN
  • 2643-3230 (ISSN-L)
  • 2643-3249
OpenAlex
W3159218044
Cited by
144
References
18
FWCI
13.32
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bortezomib Induces Anti–Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation. https://app.cochat.ai/papers/10.1158/2643-3230.bcd-21-0047
The paper
Gulla, A., Morelli, E., Samur, M. K., Botta, C., Hideshima, T., Bianchi, G., Fulciniti, M., Malvestiti, S., Prabhala, R. H., Talluri, S., Wen, K., Tai, Y.-T., Richardson, P. G., Chauhan, D., Sewastianik, T., Carrasco, R. D., Munshi, N. C., & Anderson, K. C. (2021). Bortezomib Induces Anti–Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation. Blood Cancer Discovery. https://doi.org/10.1158/2643-3230.bcd-21-0047

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.